Olema Pharmaceuticals (OLMA) said Friday that the OP-3136 molecule, which selectively inhibits lysine acetyltransferase 6 in prostate, ovarian, and non-small cell lung cancer models, has shown anti-tumor activity in preclinical studies.
The OP-3136 molecule showed potent anti-proliferative activity in multiple ovarian, NSCLC and prostate cell lines in vitro during the studies. It showed activity that was independent of KAT6 amplification or over expression, and demonstrated anti-tumor activity in vivo xenograft models of ovarian, NSCLC and prostate cancers.
The results indicate that this treatment could be effective in treating these types of tumors in addition to breast cancer, according to the announcement.
The biopharmaceutical company said it will present the preclinical data at the American Association for Cancer Research annual meeting in Chicago, Illinois, happening between April 25 and April 30.
The FDA cleared the investigational new drug application for OP-3136 in December 2024. Currently, patients are enrolling in the phase 1 clinical trial of OP-3136, the company said.
Price: 4.94, Change: -0.16, Percent Change: -3.14
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。